Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brookfield Infrastructure Partners L.P.

Chevron

Verizon

These stocks have great dividends and potential catalysts on the way.

5 High -Yield Dividend  Stocks to Watch

Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.

3 Investing Facts About Required Minimum Distributions You Need to Know - December 12, 2019 (Revised)

Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.

Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - December 11, 2019 (Revised)

Allergan

Bristol-Myers

Celgene

Eli Lilly

Medicines

Merck

Novartis

Pfizer

Sanofi

Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.

Biotech Stocks Burn A Hole In Big Pharma's Pocket. Look For More In 2020

Harley-Davidson

Kohl's

AT&T

5 cheap dividend stocks with high yields and annual increases. These dividend-paying stocks have high yields, low P/E ratios and consistently raise their dividends each year.

5 Cheap Dividend Stocks With High Yields And Annual Increases

Retirees Should Know These 3 Facts About Required Minimum Distributions - December 13, 2019

3 Investing Facts About Required Minimum Distributions You Need to Know - December 12, 2019

Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - December 11, 2019

Costamare

Crown Crafts

The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do?

3 Top Dividend Stocks to Maximize Your Retirement Income - December 09, 2019

SEATTLE, Dec.  09, 2019  (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT) today announced a multi-year, global collaboration agreement with AbbVie (NYSE: ABBV) to utilize Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to venetoclax across multiple myeloma (MM) clinical trials.

Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay

AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?

AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?

Although sales of Humira are declining in Europe, AbbVie isn’t dead in the water.

Despite the Naysayers, AbbVie Keeps Marching On

The latest ICER report doesn't paint AbbVie's new rheumatoid arthritis drug Rinvoq in as favorable a light as hoped.

3 Words AbbVie Investors Really Didn't Want to Hear

AbbVie (ABBV) closed the most recent trading day at $87.04, moving -0.79% from the previous trading session.

AbbVie (ABBV) Stock Moves -0.79%: What You Should Know

Jazz Pharmaceuticals

Zoetis

Pharmaceutical stocks rose a single-digit percentage in the first 11 months of 2019, well below their gain for 2018. Still, there are standout companies among the industry group.

Which Pharmaceutical Stocks Are Outperforming All Other Stocks?

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - December 02, 2019

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?

AbbVie (ABBV) Up 10.3% Since Last Earnings Report: Can It Continue?

Axsome Therapeutics

Vertex Pharmaceuticals

These biotech stocks cover all the bases, from great dividends to promising pipelines.

3 Top Biotech Stocks to Buy in December

Citigroup

Sonic Automotive

The stock market closed at a record high today as the DJIA rose over 42 points and the S&P 500 gained 0.4%.

3 Stocks for Value Investors to Buy as Market Reaches New High

Teva Pharmaceutical

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials.

Big Pharma Short Sellers Hike Their Bets

The Allergan deal will cement AbbVie’s position as a diversified pharmaceutical company with sustainable growth. It’s time for the shares to play catchup.

Why AbbVie Is a Dividend Growth Stock That's Too Cheap to Ignore

Extra Space Storage

Altria

Texas Instruments

Shares of AbbVie, Texas Instruments, Extra Space Storage, Altria, and 3M could be worth a spot in a yield-oriented portfolio.

Best Dividend Stocks for December 2019

Ford Motor Company

Dividend stocks are boring but predictable, but that doesn't mean young investors shouldn't look toward them to buy and hold forever.

5 Great Dividend Stocks for Young Investors

Corporate Office Properties Trust

3 Top Dividend Stocks to Maximize Your Retirement Income - November 26, 2019

GlaxoSmithKline

AbbVie and GlaxoSmithKline are both poised for a big 2020. Still, one stock is clearly the better buy right now.

Better Buy: AbbVie vs. GlaxoSmithKline

News for AbbVie Stock (ABBV)